Collaboration combines Intellia’s leading CRISPR-based platform, including its DNA writing technology, with ReCode’s proprietary Selective Organ Targeting (SORT) lipid nanoparticle (LNP) to extend the ...
A pair of privately-held developers of editing-based therapies have some successes to show for their recent efforts to address the longtime challenge of bringing their treatments to patients by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback